FGFR3 (Fibroblast Growth Factor Receptor 3)

1998-02-01   Jacky Bonaventure 

Unité INSERM 393, Hopital Necker-Enfants Malades, 149 rue de Sèvres 75743, Paris Cedex 15, France

Identity

HGNC
LOCATION
4p16.3
LOCUSID
ALIAS
ACH,CD333,CEK2,HSFGFR3EX,JTK4
FUSION GENES

DNA/RNA

Atlas Image
c-FGFR3 (4p16.3) in normal cells: PAC 1054L13 (above) and PAC 1174P18 (below) - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.

Description

16.5 Kb; 19 exons; exon 1 unknown in human

Transcription

4.0 Kb mRNA; large 3 untranslated region (1.4 kb); alternative splicing of exons 7 and 8 gives rise to two isoforms IIIb and IIIc

Proteins

Atlas Image
Protein Diagram

Description

806 amino acids; 115 kDa; tyrosine kinase receptor; contains three major domains: an extracellular domain with 3 Ig-like loops, a highly hydrophobic transmembrane domain (22 amino acids) and an intracellular domain with tyrosine kinase activity

Expression

mostly in brain, cartilage, liver, inner ear, kidney

Localisation

plasma membrane

Function

FGF receptor with tyrosine kinase activity; binding of ligand (FGF) induces receptor dimerization, autophosphorylation and signal transduction

Homology

with other FGFR (1, 2 and 4); Cek 2 in chicken

Implicated in

Disease
plasma cell leukaemia and multiple myeloma
Prognosis
unknown: found in 11 cases, but with no data on clinics
Fusion protein
no fusion protein, but promoter exchange between both partner genes
Oncogenesis
overexpression and activation of FGFR 3 provides an oncogenic signal
Entity name
squeletal dysplasia (inborn diseases)
Disease
hypochondroplasia, achondroplasia, thanatophoric dwarfism (TD I and II), Crouzon syndrome with acanthosis nigricans and coronal craniosynostosis; endochondral and membranous ossification defects are caused by recurrent missense mutations

Breakpoints

Atlas Image

Note

Chromosome 4 breakpoints are clustured in a 50-70 kb region centromeric to FGFR 3

Bibliography

Pubmed IDLast YearTitleAuthors
92077911997Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.Chesi M et al
93546761997A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.Richelda R et al
80785861994Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.Rousseau F et al
91540001997FGFR activation in skeletal disorders: too much of a good thing.Webster MK et al

Other Information

Locus ID:

NCBI: 2261
MIM: 134934
HGNC: 3690
Ensembl: ENSG00000068078

Variants:

dbSNP: 2261
ClinVar: 2261
TCGA: ENSG00000068078
COSMIC: FGFR3

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000068078ENST00000260795I6LM06
ENSG00000068078ENST00000340107P22607
ENSG00000068078ENST00000352904P22607
ENSG00000068078ENST00000412135P22607
ENSG00000068078ENST00000440486P22607
ENSG00000068078ENST00000481110F8W9L4
ENSG00000068078ENST00000507588Q96T34
ENSG00000068078ENST00000613647I6LM06

Expression (GTEx)

0
50
100
150
200
250
300
350
400

Pathways

PathwaySourceExternal ID
MAPK signaling pathwayKEGGko04010
Regulation of actin cytoskeletonKEGGko04810
Bladder cancerKEGGko05219
MAPK signaling pathwayKEGGhsa04010
Regulation of actin cytoskeletonKEGGhsa04810
Pathways in cancerKEGGhsa05200
Bladder cancerKEGGhsa05219
EndocytosisKEGGko04144
EndocytosisKEGGhsa04144
PI3K-Akt signaling pathwayKEGGhsa04151
PI3K-Akt signaling pathwayKEGGko04151
MicroRNAs in cancerKEGGhsa05206
MicroRNAs in cancerKEGGko05206
Ras signaling pathwayKEGGhsa04014
Rap1 signaling pathwayKEGGhsa04015
Rap1 signaling pathwayKEGGko04015
Signaling pathways regulating pluripotency of stem cellsKEGGhsa04550
Signaling pathways regulating pluripotency of stem cellsKEGGko04550
Central carbon metabolism in cancerKEGGhsa05230
Central carbon metabolism in cancerKEGGko05230
DiseaseREACTOMER-HSA-1643685
Diseases of signal transductionREACTOMER-HSA-5663202
Signaling by FGFR in diseaseREACTOMER-HSA-1226099
Signaling by FGFR3 in diseaseREACTOMER-HSA-5655332
FGFR3 mutant receptor activationREACTOMER-HSA-2033514
Signaling by activated point mutants of FGFR3REACTOMER-HSA-1839130
t(4;14) translocations of FGFR3REACTOMER-HSA-2033515
PI3K/AKT Signaling in CancerREACTOMER-HSA-2219528
Constitutive Signaling by Aberrant PI3K in CancerREACTOMER-HSA-2219530
Immune SystemREACTOMER-HSA-168256
Adaptive Immune SystemREACTOMER-HSA-1280218
Signaling by the B Cell Receptor (BCR)REACTOMER-HSA-983705
Downstream signaling events of B Cell Receptor (BCR)REACTOMER-HSA-1168372
PIP3 activates AKT signalingREACTOMER-HSA-1257604
Negative regulation of the PI3K/AKT networkREACTOMER-HSA-199418
Innate Immune SystemREACTOMER-HSA-168249
DAP12 interactionsREACTOMER-HSA-2172127
DAP12 signalingREACTOMER-HSA-2424491
RAF/MAP kinase cascadeREACTOMER-HSA-5673001
Fc epsilon receptor (FCERI) signalingREACTOMER-HSA-2454202
FCERI mediated MAPK activationREACTOMER-HSA-2871796
Role of LAT2/NTAL/LAB on calcium mobilizationREACTOMER-HSA-2730905
Cytokine Signaling in Immune systemREACTOMER-HSA-1280215
Signaling by InterleukinsREACTOMER-HSA-449147
Interleukin-2 signalingREACTOMER-HSA-451927
Interleukin receptor SHC signalingREACTOMER-HSA-912526
Interleukin-3, 5 and GM-CSF signalingREACTOMER-HSA-512988
Signal TransductionREACTOMER-HSA-162582
Signaling by EGFRREACTOMER-HSA-177929
GRB2 events in EGFR signalingREACTOMER-HSA-179812
SHC1 events in EGFR signalingREACTOMER-HSA-180336
GAB1 signalosomeREACTOMER-HSA-180292
Signaling by FGFRREACTOMER-HSA-190236
Signaling by FGFR3REACTOMER-HSA-5654741
FGFR3 ligand binding and activationREACTOMER-HSA-190239
FGFR3b ligand binding and activationREACTOMER-HSA-190371
FGFR3c ligand binding and activationREACTOMER-HSA-190372
Downstream signaling of activated FGFR3REACTOMER-HSA-5654708
FRS-mediated FGFR3 signalingREACTOMER-HSA-5654706
Phospholipase C-mediated cascade; FGFR3REACTOMER-HSA-5654227
SHC-mediated cascade:FGFR3REACTOMER-HSA-5654704
PI-3K cascade:FGFR3REACTOMER-HSA-5654710
Negative regulation of FGFR3 signalingREACTOMER-HSA-5654732
Signaling by Insulin receptorREACTOMER-HSA-74752
Insulin receptor signalling cascadeREACTOMER-HSA-74751
IRS-mediated signallingREACTOMER-HSA-112399
PI3K CascadeREACTOMER-HSA-109704
SOS-mediated signallingREACTOMER-HSA-112412
Signalling by NGFREACTOMER-HSA-166520
NGF signalling via TRKA from the plasma membraneREACTOMER-HSA-187037
Signalling to ERKsREACTOMER-HSA-187687
Signalling to RASREACTOMER-HSA-167044
Signalling to p38 via RIT and RINREACTOMER-HSA-187706
Prolonged ERK activation eventsREACTOMER-HSA-169893
Frs2-mediated activationREACTOMER-HSA-170968
ARMS-mediated activationREACTOMER-HSA-170984
PI3K/AKT activationREACTOMER-HSA-198203
Signaling by PDGFREACTOMER-HSA-186797
Downstream signal transductionREACTOMER-HSA-186763
Signaling by VEGFREACTOMER-HSA-194138
VEGFA-VEGFR2 PathwayREACTOMER-HSA-4420097
VEGFR2 mediated cell proliferationREACTOMER-HSA-5218921
Signaling by SCF-KITREACTOMER-HSA-1433557
MAPK family signaling cascadesREACTOMER-HSA-5683057
MAPK1/MAPK3 signalingREACTOMER-HSA-5684996
Signaling by GPCRREACTOMER-HSA-372790
Gastrin-CREB signalling pathway via PKC and MAPKREACTOMER-HSA-881907
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)REACTOMER-HSA-2404192
IGF1R signaling cascadeREACTOMER-HSA-2428924
IRS-related events triggered by IGF1RREACTOMER-HSA-2428928
Signaling by LeptinREACTOMER-HSA-2586552
Developmental BiologyREACTOMER-HSA-1266738
Axon guidanceREACTOMER-HSA-422475
NCAM signaling for neurite out-growthREACTOMER-HSA-375165
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingREACTOMER-HSA-6811558
Signaling by FGFR3 point mutants in cancerREACTOMER-HSA-8853338
Signaling by FGFR3 fusions in cancerREACTOMER-HSA-8853334
EGFR tyrosine kinase inhibitor resistanceKEGGko01521
EGFR tyrosine kinase inhibitor resistanceKEGGhsa01521
RET signalingREACTOMER-HSA-8853659

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA162373099Skeletal DysplasiaDiseaseMultilinkAnnotationassociated26555758
PA164924492brivanibChemicalPathwayassociated20124951
PA166182720erdafitinibChemicalLabelAnnotationassociated
PA26880CRKGenePathwayassociated20124951
PA28115FGF2GenePathwayassociated20124951
PA33304PIK3C2AGenePathwayassociated20124951
PA33305PIK3C2BGenePathwayassociated20124951

References

Pubmed IDYearTitleCitations
228373872012Transforming fusions of FGFR and TACC genes in human glioblastoma.255
231754432013Oncogenic FGFR3 gene fusions in bladder cancer.129
198438432009Distinct microRNA alterations characterize high- and low-grade bladder cancer.111
176684222007FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.86
232988362013The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.83
210722042010FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.79
210722042010FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.79
193810192009Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.74
211524242010Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.70
177852022007FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.67

Citation

Jacky Bonaventure

FGFR3 (Fibroblast Growth Factor Receptor 3)

Atlas Genet Cytogenet Oncol Haematol. 1998-02-01

Online version: http://atlasgeneticsoncology.org/gene/99/fgfr3-(fibroblast-growth-factor-receptor-3)